Kari Leigh Keese Sells 2,961 Shares of Axonics, Inc. (NASDAQ:AXNX) Stock

Axonics, Inc. (NASDAQ:AXNX) CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the sale, the chief financial officer now directly owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Axonics Stock Performance

AXNX opened at $69.63 on Friday. The stock has a fifty day moving average of $68.93 and a 200-day moving average of $68.05. The company has a market capitalization of $3.55 billion, a P/E ratio of -217.59 and a beta of 0.81. Axonics, Inc. has a fifty-two week low of $48.30 and a fifty-two week high of $69.91.

Axonics (NASDAQ:AXNX) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.03. Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%. The business had revenue of $114.57 million during the quarter, compared to analysts’ expectations of $112.83 million. During the same quarter in the previous year, the company earned ($0.15) EPS. The business’s revenue was up 23.3% on a year-over-year basis. On average, equities research analysts predict that Axonics, Inc. will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Axonics

Several institutional investors have recently made changes to their positions in AXNX. Hsbc Holdings PLC lifted its position in shares of Axonics by 26.5% during the 4th quarter. Hsbc Holdings PLC now owns 65,494 shares of the company’s stock valued at $4,076,000 after acquiring an additional 13,734 shares during the period. Scout Investments Inc. bought a new stake in Axonics during the fourth quarter worth about $5,858,000. Scholtz & Company LLC lifted its position in Axonics by 7.8% during the fourth quarter. Scholtz & Company LLC now owns 4,985 shares of the company’s stock worth $310,000 after purchasing an additional 360 shares during the period. Intrinsic Edge Capital Management LLC lifted its position in Axonics by 99.1% during the fourth quarter. Intrinsic Edge Capital Management LLC now owns 381,070 shares of the company’s stock worth $23,714,000 after purchasing an additional 189,716 shares during the period. Finally, Wasatch Advisors LP lifted its position in Axonics by 0.7% during the fourth quarter. Wasatch Advisors LP now owns 704,521 shares of the company’s stock worth $43,842,000 after purchasing an additional 5,046 shares during the period. 99.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a report on Monday, August 5th. Eight analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $69.57.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.